title: Delineating the anti-metastatic potential of pentoxifylline in combination with liposomal doxorubicin against breast cancer cells.
abstract: Breast cancer remains the second most prevalent cancer worldwide. Several anticancer drugs are being currently used in the treatment of breast cancer. However, owing to high cytotoxicity, induced resistance and cost ineffectiveness, there is an urgent need to develop newer therapeutic regimens that limit the current problems. One of the approaches in this regard is the formulation of combination therapies whereby multiple drugs are being delivered at relatively lesser dose that surely confines the aforesaid problems. In this purview, we had evaluated the effects of pentoxifylline, a methylxanthine derivative and liposomal doxorubicin (Lipodox), an anthracycline in combination to evaluate their anti-metastatic activities both in vitro and in vivo against breast cancer cells. The combination regime exhibited synergistic activity and inhibited cellular proliferation to a greater extent with regard to each drug used alone.
authors.affiliation: Gude Lab, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India. Electronic address: peeyushgoel29@gmail.com.
authors.forename: Peeyush N
authors.initials: PN
authors.lastname: Goel
authors.affiliation: Gude Lab, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India. Electronic address: rgude@actrec.gov.in.
authors.forename: Rajiv P
authors.initials: RP
authors.lastname: Gude
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D018929:Cell Culture Techniques; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology*; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D010431:Pentoxifylline / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D023041:Xenograft Model Antitumor Assays
chemical_list: C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D010431:Pentoxifylline
keywords: Breast cancer; Combination therapy; Lipodox; Pentoxifylline; Xenograft model